Page last updated: 2024-12-08
pyrrolidino-benzylphenoxyethanamine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 164472 |
| CHEMBL ID | 14608 |
| SCHEMBL ID | 7140970 |
| MeSH ID | M0220505 |
Synonyms (15)
| Synonym |
|---|
| pyrrolidino-benzylphenoxyethanamine |
| 1-[2-(4-benzyl-phenoxy)-ethyl]-pyrrolidine |
| bdbm50085279 |
| CHEMBL14608 , |
| 27P , |
| 1-[2-(4-benzylphenoxy)ethyl]pyrrolidine |
| 147664-41-3 |
| pyrrolidine, 1-(2-(4-(phenylmethyl)phenoxy)ethyl)- |
| SCHEMBL7140970 |
| pyrolidino-bpe |
| pyrrolidine,1-[2-[4-(phenylmethyl)phenoxy]ethyl]- |
| DTXSID70163772 |
| 1-(2-(4-benzylphenoxy)ethyl)pyrrolidine |
| pyrrolidine, 1-[2-[4-(phenylmethyl)phenoxy]ethyl]- |
| Q27452773 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Leukotriene A-4 hydrolase | Homo sapiens (human) | IC50 (µMol) | 0.0260 | 0.0005 | 1.2854 | 7.6500 | AID99747; AID99748; AID99749 |
| Leukotriene B4 receptor 1 | Homo sapiens (human) | IC50 (µMol) | 0.0260 | 0.0008 | 0.3091 | 3.2500 | AID99748 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (15)
Molecular Functions (13)
Ceullar Components (8)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Leukotriene A-4 hydrolase | Homo sapiens (human) |
| nucleoplasm | Leukotriene A-4 hydrolase | Homo sapiens (human) |
| cytosol | Leukotriene A-4 hydrolase | Homo sapiens (human) |
| extracellular exosome | Leukotriene A-4 hydrolase | Homo sapiens (human) |
| tertiary granule lumen | Leukotriene A-4 hydrolase | Homo sapiens (human) |
| ficolin-1-rich granule lumen | Leukotriene A-4 hydrolase | Homo sapiens (human) |
| cytosol | Leukotriene A-4 hydrolase | Homo sapiens (human) |
| nucleus | Leukotriene A-4 hydrolase | Homo sapiens (human) |
| plasma membrane | Leukotriene B4 receptor 1 | Homo sapiens (human) |
| plasma membrane | Leukotriene B4 receptor 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (9)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID99748 | In vitro inhibition of recombinant human leukotriene A4 hydrolase. | 2003 | Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6 | Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolase. |
| AID99749 | Inhibition of leukotriene A4 hydrolase in human recombinant assay | 2002 | Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23 | Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase. |
| AID138599 | Percent inhibition was determined at a dose of 10 mg/Kg in mouse ex vivo assay | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | Structure-activity relationship studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A(4) (LTA(4)) hydrolase. |
| AID223081 | Inhibitory activity was determined for LTB4 production in human whole blood. | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | Structure-activity relationship studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A(4) (LTA(4)) hydrolase. |
| AID138548 | Ex vivo inhibition of LTB4 production in mouse whole blood at 10 mg/kg | 2002 | Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23 | Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase. |
| AID92873 | Inhibition of LTB4 production from whole human blood. | 2003 | Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6 | Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolase. |
| AID99747 | Inhibitory activity was determined against Leukotriene A4 hydrolase | 2000 | Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4 | Structure-activity relationship studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A(4) (LTA(4)) hydrolase. |
| AID92878 | Inhibition of leukotriene B4 production in human whole blood | 2002 | Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23 | Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase. |
| AID116343 | Ex vivo inhibition of LTB4 production in mouse whole blood following 10 mg/kg p.o. administration. | 2003 | Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6 | Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||